Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration
June 23 2022 - 4:05PM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced a partnership with Epic,
the industry leading healthcare software company, to integrate
Myriad’s full line of genetic tests with Epic’s expansive network
of 600,000 physicians and more than 250 million patients.
The integration creates a seamless, end-to-end workflow solution
for healthcare providers to order Myriad tests and review results
directly within their everyday Epic platform without additional
steps or manual ordering processes. Epic enables a secure exchange
of information between healthcare institutions that care for
patients.
With the ability to review pertinent health information, order
tests, and receive results natively in Epic, providers will have
the critical genetic insights and related information they need to
drive better health outcomes and improve the patient experience.
Patients will also be able to easily access their Myriad test
results and other health information directly within their EHR
portal.
“Simplifying the process of genetic testing by making it more
accessible and interoperable with electronic health records is a
key component of our mission to advance health and well-being for
all,” said Paul J. Diaz, president and CEO, Myriad Genetics. “Our
collaboration with Epic reflects our strategy to partner with other
healthcare industry leaders so we can advance precision medicine
together. Increasing access to genetic insights and integrating our
tests into Epic’s vast network of healthcare systems represents a
significant step forward to better serve patients and healthcare
providers.”
As part of its transformation and growth plan, Myriad is
focusing on new customer-centric, tech-enabled tools to make the
genetic testing process easier for patients and clinicians. With
the recent launch of Myriad’s Precise Oncology Solutions, providers
can now place a single order for multiple Myriad tests and receive
timely results through a unified online portal. Now, through the
partnership with Epic, Myriad is expanding efforts to help
physicians and health systems gain access to genetic testing faster
and conveniently within the platform they use every
day.
“Genetic testing and precision medicine save lives,” said Alan
Hutchison, vice president of Population Health at Epic. “Through
this relationship, we’re bringing genetic insights to the point of
care at scale, giving providers and patients the information they
need to make more timely, informed decisions.”
Myriad’s integration with Epic is expected to go live later this
year.
About Myriad Genetics Myriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and
commercializes genetic tests that help assess the risk of
developing disease or disease progression and guide treatment
decisions across medical specialties where genetic insights can
significantly improve patient care and lower healthcare costs. Fast
Company named Myriad among the World’s Most Innovative Companies
for 2022. For more information, visit www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx,
Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary
Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify,
Foresight, Precise, FirstGene, Health.Illuminated., RiskScore,
Prolaris, GeneSight, and EndoPredict are trademarks or registered
trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc.
All rights reserved.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to the integration of the company’s genetic
tests with Epic’s network of physicians and patients and the
expected timing of the integration; the company’s growth plan to
scale customer-centric, tech-enabled commercial capabilities with
600+ EHR integrations this year; the anticipated benefits of the
integration, including that the integration will create an
end-to-end workflow solution for healthcare providers to order
Myriad tests and review results directly with their everyday Epic
workflows, provide providers with critical genetic insights and
related information they need to drive better health outcomes and
improve the patient experience, and allow patients to easily access
their Myriad test results directly from their EHR portal; and the
company’s strategic imperatives under the caption “About Myriad
Genetics.” These “forward-looking statements” are management’s
present expectations of future events and are subject to a number
of risks and uncertainties that could cause actual results to
differ materially and adversely from those described in the
forward-looking statements. These risks include, but are not
limited to: uncertainties associated with COVID-19, including its
possible effects on the company’s operations and the demand for its
products and services and the company’s ability to efficiently and
flexibly manage its business; the risk that sales and profit
margins of the company’s existing molecular diagnostic tests may
decline or that the company may not be able to operate its business
on a profitable basis; risks related to the company’s ability to
generate sufficient revenue from its existing product portfolio or
in launching and commercializing new tests; risks related to
changes in governmental or private insurers’ coverage and
reimbursement levels for the company’s tests or the company’s
ability to obtain reimbursement for its new tests at comparable
levels to its existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that the company may be unable to develop or
achieve commercial success for additional molecular diagnostic
tests in a timely manner, or at all; the risk that the company may
not successfully develop new markets for its molecular diagnostic
tests, including the company’s ability to successfully generate
revenue outside the United States; the risk that licenses to the
technology underlying the company’s molecular diagnostic tests and
any future tests are terminated or cannot be maintained on
satisfactory terms; risks related to delays or other problems with
operating and constructing the company’s laboratory testing
facilities; risks related to public concern over genetic testing in
general or the company’s tests in particular; risks related to
regulatory requirements or enforcement in the United States and
foreign countries and changes in the structure of the healthcare
system or healthcare payment systems; risks related to the
company’s ability to obtain new corporate collaborations or
licenses and acquire or develop new technologies or businesses on
satisfactory terms, if at all; risks related to the company’s
ability to successfully integrate and derive benefits from any
technologies or businesses that it licenses, acquires or develops;
risks related to the company’s projections about the potential
market opportunity for the company’s current and future products;
the risk that the company or its licensors may be unable to protect
or that third parties will infringe the proprietary technologies
underlying the company’s tests; the risk of patent-infringement
claims or challenges to the validity of the company’s patents;
risks related to changes in intellectual property laws covering the
company’s molecular diagnostic tests, or patents or enforcement, in
the United States and foreign countries; risks related to security
breaches, loss of data and other disruptions, including from
cyberattacks; risks of new, changing and competitive technologies
and regulations in the United States and internationally; the risk
that the company may be unable to comply with financial operating
covenants under the company’s credit or lending agreements; risks
related to the material weakness related to general information
technology controls, including the impact thereof and the company’s
remediation plan, and its ability to achieve and maintain effective
disclosure controls and procedures and internal control over
financial reporting; risks related to current and future lawsuits,
including product or professional liability claims; and other
factors discussed under the heading “Risk Factors” contained in
Item 1A of the company’s Annual Report on Form 10-K filed with the
Securities and Exchange Commission on February 25, 2022, as well as
any updates to those risk factors filed from time to time in the
company’s Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. The reported number of physicians and patients in Epic’s
network were provided by Epic.
Media
Contact:Megan Manzari(385)
318-3718Megan.Manzari@myriad.com |
Investor Contact: Nathan Smith(801)
505-5067Nathan.Smith@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024